Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2021 07:35 ET | Source: Arch Biopartners

Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...
June 10, 2021 07:20 ET | Source: Arch Biopartners

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
September 18, 2018 15:34 ET | Source: Alion Canada

Alion Canada Invests in UBC’s Naval Architecture and Marine Engineering Program

OTTAWA, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Alion Canada is pleased to announce a $200,000 investment into the University of British Columbia’s (UBC) Naval Architecture and Marine Engineering (NAME)...